We are live on ! Find out more
GANX icon

Gain Therapeutics

50 hedge funds and large institutions have $14.6M invested in Gain Therapeutics in 2026 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

504% more call options, than puts

Call options by funds: $912K | Put options by funds: $151K

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

0% more funds holding

Funds holding: 50 → 50 (0)

0.95% less ownership

Funds ownership: 20.3% → 19.35% (-0.95%)

9% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 11

26% less capital inflows, than outflows

Capital inflows: $1.25M | Capital outflows: $1.69M

Holders
50
Holders Change
–
Holders Change %
0%
% of All Funds
0.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
10
Reduced
11
Closed
9
Calls
$912K
Puts
$151K
Net Calls
+$761K
Net Calls Change
+$587K

GANX Hedge Fund Activity: Q3 2026 in Review

50 of the 8,114 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q3 2026, worth a combined $14.6M — down 16% from $17.4M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new GANX positions and 9 closed out — a net gain of 1 holder — while 10 added to existing stakes and 11 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $333K. The largest seller was Marshall Wace, cutting an estimated $443K.

  • 50 institutional investors held Gain Therapeutics (GANX) as of Q3 2026, unchanged from Q2 2026.
  • Funds reported $14.6M of Gain Therapeutics stock for Q3 2026, down 16% quarter-over-quarter.
  • 10 funds opened new Gain Therapeutics positions in Q3 2026 and 9 closed out, a net change of +1 holder.
  • The largest Gain Therapeutics buyer in Q3 2026 was Renaissance Technologies, an estimated $333K added.
  • The largest Gain Therapeutics seller in Q3 2026 was Marshall Wace, an estimated $443K sold.

Based on aggregated 13F filings for Q3 2026.